Forward Pharma A/S
FWPAY · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | -0.17 | 0.23 | 0.05 |
| FCF Yield | -4.85% | -10.16% | -4.34% | -34.33% |
| EV / EBITDA | 3.66 | 54.93 | 4.34 | 2.63 |
| Quality | ||||
| ROIC | -5.47% | -4.31% | -6.81% | -14.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.25 | 0.89 | 0.53 | 1.66 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 58.71% | -156.07% | 84.91% | -101.57% |
| Safety | ||||
| Net Debt / EBITDA | 11.71 | 190.11 | 12.85 | 5.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |